Back to Browse Journals » Clinical Interventions in Aging » Volume 3 » Issue 3

Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women

Authors Irene Lambrinoudaki, Sophia Vlachou, Fotini Galapi, Dimitra Papadimitriou, K Papadias

Published Date October 2008 Volume 2008:3(3) Pages 445—451

DOI http://dx.doi.org/10.2147/CIA.S2046

Published 2 October 2008

Irene Lambrinoudaki, Sophia Vlachou, Fotini Galapi, Dimitra Papadimitriou, K Papadias

2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, Greece

Abstract: Zoledronic acid is a nitrogen-containing, third-generation bisphosphonate that has recently been approved for the treatment of postmenopausal osteoporosis as an annual intravenous infusion. Zoledronic acid is an antiresorptive agent which has a high affinity for mineralized bone and especially for sites of high bone turnover. Zoledronic acid is excreted by the kidney without further metabolism. Zoledronic acid administered as a 5 mg intravenous infusion annually increases bone mineral density in the lumbar spine and femoral neck by 6.7% and 5.1% respectively and reduces the incidence of new vertebral and hip fractures by 70% and 41% respectively in postmenopausal women with osteoporosis. Most common side effects are post-dose fever, flu-like symptoms, myalgia, arthralgia, and headache which usually occur in the first 3 days after infusion and are self-limited. Rare adverse effects include renal dysfunction, hypocalcemia, atrial fibrillation, and osteonecrosis of the jaw.

Keywords: zoledronic acid, postmenopausal osteoporosis, bisphosphonate

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Epidemiology and management of osteoporosis in the People’s Republic of China: current perspectives

Lin X, Xiong D, Peng YQ, Sheng ZF, Wu XY, Wu XP, Wu F, Yuan LQ, Liao EY

Clinical Interventions in Aging 2015, 10:1017-1033

Published Date: 25 June 2015

Effect of nanoparticles binding ß-amyloid peptide on nitric oxide production by cultured endothelial cells and macrophages

Orlando A, Re F, Sesana S, Rivolta I, Panariti A, Brambilla D, Nicolas J, Couvreur P, Andrieux K, Masserini M, Cazzaniga E.

International Journal of Nanomedicine 2013, 8:1335-1347

Published Date: 15 April 2013

Actively-targeted LTVSPWY peptide-modified magnetic nanoparticles for tumor imaging

Jie L-Y, Cai L-L, Wang L-J, Ying X-Y, Yu R-S, Zhang M-M,Du Y-Z

International Journal of Nanomedicine 2012, 7:3981-3989

Published Date: 24 July 2012

Nanofiber composites containing N-heterocyclic carbene complexes with antimicrobial activity

Elzatahry AA, Al-Enizi AM, Elsayed EA, Butorac RR, Al-Deyab SS, Wadaan MAM, Cowley AH

International Journal of Nanomedicine 2012, 7:2829-2832

Published Date: 7 June 2012

Comparative manufacture and cell-based delivery of antiretroviral nanoformulations

Balkundi S, Nowacek AS, Veerubhotla RS, Chen H, Martinez-Skinner A, Roy U, Mosley RL, Kanmogne G, Liu X, Kabanov AV, Bronich T, McMillan J, Gendelman HE

International Journal of Nanomedicine 2011, 6:3393-3404

Published Date: 20 December 2011

Use of cross-linked carboxymethyl cellulose for soft-tissue augmentation: preliminary clinical studies

Mauro Leonardis, Andrea Palange, Rodrigo FV Dornelles, et al

Clinical Interventions in Aging 2010, 5:317-322

Published Date: 9 November 2010

The inclusion of cognition in vascular risk factor clinical practice guidelines

Kenneth Rockwood, Laura E Middleton, Paige K Moorhouse, et al.

Clinical Interventions in Aging 2009, 4:425-433

Published Date: 2 November 2009

Management of attention-deficit hyperactivity disorder in adults: focus on methylphenidate hydrochloride

Rajasree Nair, Shannon B Moss

Neuropsychiatric Disease and Treatment 2009, 5:421-432

Published Date: 10 August 2009

Dietary habits and cardiovascular disease risk in middle-aged and elderly populations: a review of evidence

Eleni Tourlouki, Antonia-Leda Matalas, Demosthenes B Panagiotakos

Clinical Interventions in Aging 2009, 4:319-330

Published Date: 14 July 2009